MedTrace Logo

Effects of Mitopure (Urolithin A) on Skeletal Muscle Function, Iron Metabolism and Endurance Performance

NCT04783207 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2023-08-31

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo-controlled study enrolling 36 (16 Elite and 20 Sub-Elite trained endurance runners (18 placebo and 18 Mitopure intervention) who are 18-40 years of age. Mitopure or Placebo supplement, will be given as a daily oral dose for 4-weeks.

Conditions

  • Healthy

Interventions

DIETARY_SUPPLEMENT

Mitopure

Softgel containing 250 mg of Urolithin A (Mitopure) with excipients. 4 soft-gels to be taken daily

DIETARY_SUPPLEMENT

Placebo

Softgel containing only excipients. 4 soft-gels to be taken daily

Sponsors & Collaborators

  • Australian Catholic University

    collaborator OTHER

  • Amazentis SA

    lead INDUSTRY

Principal Investigators

  • Louise Burke, OAM PhD · Australian Catholic University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-04-21
Primary Completion
2022-05-30
Completion
2023-08-30

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04783207 on ClinicalTrials.gov